Cardiovascular Benefit of Colchicine in Relation to Baseline Risk: A Secondary Analysis of the LoDoCo2 Trial
J Am Heart Assoc. 2025 May 15:e038687. doi: 10.1161/JAHA.124.038687. Online ahead of print.ABSTRACTBACKGROUND: The LoDoCo2 (Low-Dose Colchicine 2) trial showed that colchicine reduced the risk for cardiovascular events in patients with chronic coronary syndrome. Current guidelines recommend colchici